The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
The Food and Drug Administration missed the deadline for making a decision regarding a Covid-19 vaccine from Novavax (NVAX), Liz Essley Whyte ...
It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...
The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.
Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “Novavax can confirm that April 1, 2025, was the ...
Novavax (NasdaqGS:NVAX) recently experienced a significant decline of 21% over the past week, coinciding with leadership changes, including the retirement of longtime Chairman James Young and the ...
The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...